MedPath

Efficacy and Safety of the Alena App as a Treatment for Social Anxiety Disorder

Not Applicable
Completed
Conditions
Social Anxiety
Social Anxiety Disorder
Social Anxiety Disorder (Social Phobia)
Registration Number
NCT05987969
Lead Sponsor
Aya Technologies Limited
Brief Summary

The present study is a randomised controlled trial that seeks to investigate the efficacy and safety of the Alena app as a treatment for social anxiety disorder.

Detailed Description

This will be a 10-week web-based parallel-group unblinded randomised controlled trial with an 8-week intervention period and a 2-week follow-up post-intervention. Participants will be randomly allocated to receive access to the Alena app or to a wait list control group, in a 1:1 ratio. The Alena app primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
250
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in Social Phobia Inventory (SPIN)Change from baseline SPIN at 8 weeks

The SPIN was designed to assess the full spectrum of symptoms that characterise social anxiety, including fear, avoidance and physiological components.

Change in Work and Social Adjustment Scale (WSAS)Change from baseline WSAS at 8 weeks

The WSAS measures the extent to which the respondent's problem impairs their ability to carry out day-to-day activities, such as work, home management and social leisure activities.

Secondary Outcome Measures
NameTimeMethod
Change in Social Phobia Inventory (SPIN)Change from SPIN level at the end of the intervention period at 4 weeks later

The SPIN was designed to assess the full spectrum of symptoms that characterise social anxiety, including fear,

Work and Social Adjustment Scale (WSAS)At the follow-up point of 4 weeks after the end of the intervention period.

The WSAS measures the extent to which the respondent's problem impairs their ability to carry out day-to-day

Serious adverse eventsWithin the intervention period of 8 weeks

Serious adverse events are defined as those that meet the criteria for ISO:14155(A:14)

Trial Locations

Locations (1)

Aya Technologies Limited

🇬🇧

London, United Kingdom

Aya Technologies Limited
🇬🇧London, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.